Polkadot has decelerated and its roadmap has delays and uncertainties. Conversely, Lyno AI is becoming a market leader in the crypto presale, with a high initial demand and an attractive ROI.   Early Bird Presale: Why Whales Are Positioning Before the Price Jumps The Lyno AI presale is on its Early Bird round at $0.05 per […] The post Polkadot Growth Slows While Lyno AI Emerges as a Top Presale Contender appeared first on Live Bitcoin News.Polkadot has decelerated and its roadmap has delays and uncertainties. Conversely, Lyno AI is becoming a market leader in the crypto presale, with a high initial demand and an attractive ROI.   Early Bird Presale: Why Whales Are Positioning Before the Price Jumps The Lyno AI presale is on its Early Bird round at $0.05 per […] The post Polkadot Growth Slows While Lyno AI Emerges as a Top Presale Contender appeared first on Live Bitcoin News.

Polkadot Growth Slows While Lyno AI Emerges as a Top Presale Contender

2025/10/01 16:44
3 min read

Polkadot has decelerated and its roadmap has delays and uncertainties. Conversely, Lyno AI is becoming a market leader in the crypto presale, with a high initial demand and an attractive ROI.  

Early Bird Presale: Why Whales Are Positioning Before the Price Jumps

The Lyno AI presale is on its Early Bird round at $0.05 per token. 806,644 tokens have been sold and $40,332 raised toward the $0.10 final target. In the next stage the price will increase to $0.055, therefore early involvement is welcome.

Lyno AI also provides a Giveaway program. Purchasers above $100 will be able to win a portion of 100,000 tokens, which will be divided into ten prizes with 10,000 tokens each. The prize enhances presale urgency and encourages loyal fans.

Why Lyno AI’s AI Arbitrage Engine Leaves Polkadot’s Roadmap Behind

Lyno AI leverages state-of-the-art AI-based cross-chain arbitrage. Its neural-network code scans blockchains continuously to identify and automatically trade on arbitrage opportunities. Such speed and intelligence are faster than the old-fashioned parachain models used by Polkadot.

The completely autonomous platform of Lyno AI opens arbitrage to retail investors, leveling the playing field where institutions once dominated. Verified Cyberscope -audited smart contracts provide users with safety and trust.

Multi-Chain Execution, AI Precision, and Community Power—Why Investors Are Taking Notice

Lyno AI provides unprecedented liquidity and execution efficiency to users with multi-chain support including Ethereum, BNB Chain, Polygon, Arbitrum, Optimism, and more than a dozen other chains. It is governed by LYNO token holders, guaranteeing a decentralized and flexible ecosystem.

Analysts Predict 7,900% ROI—Will You Still Be Watching From the Sidelines?

Individuals who missed the explosive gains of Solana and Avalanche now have a second opportunity with Lyno AI. Analysts forecast up to 7,900% ROI by the end of 2025. Investors should move now and purchase at the Early Bird price of $0.05 before the next price increase.

Lyno AI integrates AI-based trading with robust community regulation and audited contracts. The 100K token giveaway further rewards early supporters, adding fuel to presale momentum.

Conclusion: Lyno AI Is the Audited, AI-Driven Breakout Asset Polkadot Couldn’t Be

To find the next breakout asset, move quickly to buy Lyno AI tokens before this competitor leaves the pack. Lyno AI is the first cross-chain arbitrage trading protocol audited by Cyberscope and powered by cutting-edge AI.

Get in on the Lyno AI presale now and become a leader of the next massive crypto wave.

 For more information about LYNO visit the links below:

Website:https://lyno.ai/  

Buy Presale- https://lyno.ai/#presale 

Whitepaper: https://lyno.ai/whitepaper.pdf 

Twitter/X: https://x.com/Lyno_AI 

Telegram:https://t.me/lyno_ai 

Win 100k: https://gleam.io/KCCV3/lyno-ai-giveaway 

Contact Details:
LYNO AI
contact@lyno.ai

Disclaimer: This is a paid post and should not be treated as news/advice. LiveBitcoinNews is not responsible for any loss or damage resulting from the content, products, or services referenced in this press release.

The post Polkadot Growth Slows While Lyno AI Emerges as a Top Presale Contender appeared first on Live Bitcoin News.

Market Opportunity
null Logo
null Price(null)
--
----
USD
null (null) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

And the Big Day Has Arrived: The Anticipated News for XRP and Dogecoin Tomorrow

And the Big Day Has Arrived: The Anticipated News for XRP and Dogecoin Tomorrow

The first-ever ETFs for XRP and Dogecoin are expected to launch in the US tomorrow. Here's what you need to know. Continue Reading: And the Big Day Has Arrived: The Anticipated News for XRP and Dogecoin Tomorrow
Share
Coinstats2025/09/18 04:33
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Rising Altcoin Inflows Signal Potential Market Sell-Off: CryptoQuant

Rising Altcoin Inflows Signal Potential Market Sell-Off: CryptoQuant

        Highlights:  Inflows of altcoins in exchanges have surged by 22% in early 2026. An increase in deposits indicates a growing sell-side pressure. The 
Share
Coinstats2026/02/22 02:03